* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download The Future of Psychiatric Research: Genomes and Neural
Discovery and development of beta-blockers wikipedia , lookup
Pharmacognosy wikipedia , lookup
Pharmacogenomics wikipedia , lookup
5-HT2C receptor agonist wikipedia , lookup
5-HT3 antagonist wikipedia , lookup
Polysubstance dependence wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Prescription costs wikipedia , lookup
Theralizumab wikipedia , lookup
Drug design wikipedia , lookup
Discovery and development of angiotensin receptor blockers wikipedia , lookup
NMDA receptor wikipedia , lookup
Drug interaction wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Nicotinic agonist wikipedia , lookup
Drug discovery wikipedia , lookup
Cannabinoid receptor antagonist wikipedia , lookup
NK1 receptor antagonist wikipedia , lookup
Psychopharmacology wikipedia , lookup
Where Are We Heading? Patricia Brown, PhD, ARNP New ADTs This Decade o Oleptro (extended release Trazodone) 2010 o Viibryd (Vilazodone) 2011 o Fetzima (Levomilnacipran) 2013 o Brintellix (Vortioxetine) 2013 313 Psychiatric Drugs in Development o Dementia (90 Investigational Products) o Depression (71 Investigational Products ) o Schizophrenia (54 Investigational Products) o Anxiety Disorders (38 Investigational Products) The NIMH Priority for Psychiatric Drug Development: o Rapid acting antidepressant o Generation of antipsychotics which assists with cognition o Autism medication which addresses prosocial components Ketamine infusions for treatment resistant depression ALKS 5461 Blocking the Kappa Receptor o When Dynorphin are released=Depression o Blocking this stimulates ADT action o High levels of Dynorphin block glutamate. Glutamate is thought to prevent neuroplasticity and prevent poor learning abilities and prevent learned helplessness. AVP-786 is a modified dextromethorphan which is an uncompetitive NMDA receptor antagonist, sigma-1 receptor agonist and inhibitor of the serotonin transporter (SERT) and norepinephrine (NET) transporter As of Jan 2015 There Are 5 New Anxiety Investigation Products o Most popular drug still are BDZs o The goal –to find as efficacious a drug without the sedative side effects or addictive potential Aloradine (PH94B) o o o A vomeropherine neuroactive steriod drug Under development as a nasal spray formulation For the acute treatment of social anxiety disorder in women. B-GOS o Galacto-oligosaccharides belong to the group of prebiotics. o Prebiotics are defined as non-digestible food ingredients that beneficially affect the host by stimulating the growth and/or activity of beneficial bacteria in the colon. IW-2143 (BNC210) S32212 o a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant SL-651,498 o o a GABAA receptor agonist with subtypeselective efficacy, as a potential treatment for generalized anxiety disorder an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptors. Translocator Protein (18 kD) o Peripheral benzodiazepine receptor specific ligands induce microglia functions consistent with an activated state. TMS Over 30 New Medications in Development for Schizophrenia May 2014 Caripazine (RGH-188) o D2, D3 antagonist LY2140023 o o Prodrug for an mGluR2/3 agonist Phase three development Brexpiprazole OPC-34712 o a novel D2 dopamine partial agonist What is in the works for Cognition and social skill development in autism Autism Drugs in Development o o o o o o o AT001 ( uoxetine rapid dissolve) ORPHAN DRUG CM-AT Rye, NY (Fast Track) application submitted www.curemark.com CNDO-201 (Trichuris suis ova) Coronado Biosciences autism Phase II www.coronadobiosciences.com Memantine Forest Laboratories Phase II completed RG7314 (vasopressin-1 receptor antagonist) Autism Phase II Syntocinon nasal spray Retrophin Arbaclofen or STX209, is a derivative of the FDA-approved drug, baclofen NIMH Strategic Objectives o o o o Promote discovery in the brain and behavioral sciences to fuel research on the causes of mental disorders Chart mental illness trajectories to determine when, where and how to intervene Develop new and better interventions that incorporate the diverse needs and circumstances of people with mental illnesses Strengthen the public health impact of NIMHsupported research o Thank You for Your Attention! References o o Huda Akil, Sydney Brenner, Eric Kandel, Kenneth S. Kendler, Mary-Claire King, Edward Scolnick, James D. Watson, and Huda Y. Zoghbi; The Future of Psychiatric Research: Genomes and Neural Circuits. Science 26 March 2010: 1580-1581. Steven M. Paul, Daniel S. Mytelka, Christopher T. Dunwiddie, Charles C. Persinger, Bernard H. Munos, Stacy R. Lindborg, Aaron L. Schacht ; How to improve R&D productivity: the pharmaceutical industry's grand challenge .Nature Reviews Drug Discovery 9, 203-214 (19 February 2010)